Evidence map›Paper›PMID 30922893›Full record

ArticleNeuropharmacology2019

Sensitization to the prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA).

Daniel W Curry, Laís F Berro, Andie R Belkoff, Agnieszka Sulima, Kenner C Rice, Leonard L Howell

Open access · greenAbstract read
In one paragraph

Article in Neuropharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Therapeutic mechanisms of psychedelics and entactogens.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Review
  7. Article
  8. Article
  9. Systemic enhancement of serotonin signaling reverses social deficits in multiple mouse models for ASD.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Daniel W CurryDivision of Neuropharmacology and Neurologic Diseases, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Laís F BerroDivision of Neuropharmacology and Neurologic Diseases, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Andie R BelkoffDivision of Neuropharmacology and Neurologic Diseases, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA.
Agnieszka SulimaDrug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA.
Kenner C RiceDrug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA.
Leonard L HowellDivision of Neuropharmacology and Neurologic Diseases, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA; Department of Psychiatry and Behavioral Science, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: lhowell@emory.edu.
Emory University · USNational Institute on Alcohol Abuse and Alcoholism · USNational Institute on Drug Abuse · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Medicinal Chemistry of Drugs Acting on Biogenic Amine ReceptorsZIADA000532 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI RICE, KENNER · 2009 to 2020
$4.5M
Training Program in Neurobiology of Drug AbuseT32DA015040 · NIDA · EMORY UNIVERSITY · PI KUHAR, MICHAEL J · 2003 to 2012
$3.6M
Neuropharmacology of Abused Stimulants in Nonhuman PrimatesK05DA031246 · NIDA · EMORY UNIVERSITY · PI HOWELL, LEONARD L · 2012 to 2016
$619k
Medicinal Chemistry of Drugs Acting on Biogenic Amine ReceptorsZ01DA000532 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI RICE, KENNER · 2008 to 2008
$117k
Intramural NIH HHS Z01 DA000532NIDA NIH HHS K05 DA031246NIDA NIH HHS T32 DA015040NIH HHS P51 OD011132
6 · The paper itself

Abstract

The recreational drug 3,4-methylenedioxymethamphetamine (MDMA) has well documented prosocial effects and is currently under clinical investigation as a treatment for patients with PTSD, autism, and other conditions. Early clinical trials have found that MDMA-assisted therapy may have robust long-lasting therapeutic effects, yet the mechanism by which acute treatments produce these long-term effects is unclear. Sensitization to certain behavioral drug effects is a common rodent model used to assess long-lasting neurobiological adaptations induced by acute drug treatments. Nine independent experiments were undertaken to investigate if and how mice sensitize to the prosocial effects of MDMA. When treated with 7.8 mg/kg MDMA and paired every other day for a week, MDMA-induced social interaction increased precipitously across treatment sessions. This previously unreported phenomenon was investigated and found to be heavily influenced by a social context and 5-HT

Indexed as

Social BehaviorAnimalsBehavior, AnimalFluorobenzenesMaleMiceMotor ActivityN-Methyl-3,4-methylenedioxyamphetaminePiperidinesSerotonin AgentsSerotonin AntagonistsFluorobenzenesN-Methyl-3,4-methylenedioxyamphetaminePiperidinesSerotonin AgentsSerotonin Antagonistsvolinanserin3,4-methylenedioxymethamphetamine5-HT(2A)MDMASensitizationSocial interaction

Identifiers

PMID30922893
PMCPMC8364737
OpenAlexW2927414016

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.